Pulse Biosciences, Inc. announced CellFX System regulatory progress updates. Received notification from the Food and Drug Administration (FDA) that the company’s 510(k) submission for a general dermatology indication for the CellFX System has advanced from Substantive Review to Interactive Review. Completed all treatments in the company’s previously announced pivotal comparison study to evaluate the treatment of sebaceous hyperplasia (SH) using the CellFX System, with the planned specific indication 510(k) submission as early as the end of the first quarter of 2021. Obtained FDA Investigational Device Exemption (IDE) approval of a pivotal comparison study to evaluate the treatment of cutaneous non-genital warts using the CellFX System, with enrollment expected to begin by the end of the first quarter of 2021. Continued review by the Notified Body of the CellFX System for CE mark approval and Health Canada for Medical Device License remains on track.